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Respiratory syncytial virus (RSV) belongs to Paramyxoviridae family of enveloped negative-strand RNA viruses and causes
severe bronchiolitis and pneumonia in children younger than 2 years of age. As members of Paramyxoviridae family, RSV and
parainfluenza type 3 (PIV3) have similar modes of infection and replication. A variety of negative-strand RNA virus infections,
including that of PIV3, are inhibited by human MxA protein, a type I interferon (IFN)-inducible GTPase. We tested whether the
MxA protein, induced either by type I human IFNs or by stable transfection of human MxA gene in human (U-87) or simian
(Vero) cells, confers resistance to these cells against infection by RSV strain A2. RSV infection was resistant to antiviral
effects induced by 0–10,000 U/ml type I IFNs (IFN-a or -b) in both human lung epithelial, A549, and fibroblast, MRC-5 cells.
RSV virus yield was reduced only by 10- to 20-fold, and viral protein synthesis was not significantly affected under conditions
of IFN treatment where PIV3 yield was reduced by 1000- to 10,000-fold. Human or simian cell lines constitutively expressing
MxA were protected against infection by PIV3 but not by RSV. Our results indicate that RSV A2 is resistant to the antiviral
effects of MxA, even though RSV and PIV3 have similar replication strategies. In IFN-treated coinfected cultures, IFN-
resistant RSV A2 did not prevent the IFN-mediated inhibition of PIV3 multiplication. Hence the resistance of RSV A2 to type
I IFNs does not appear to be due to soluble factors released into the medium or a disruption in the cellular antiviral machinery
brought about by RSV A2 infection.
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lINTRODUCTION
Interferons (IFNs) are a heterogeneous family of cyto-
ines with demonstrated antiviral, antitumor, and immu-
omodulatory activities (Pestka et al., 1987). Their antivi-
al action is initiated via binding to species-specific cell
urface receptors resulting in activation of IFN-stimu-
ated genes (ISGs) and induction of a variety of intracel-
ular proteins that inhibit viral replication via distinct
echanisms (Staeheli, 1990; Samuel, 1991; Anderson et
l., 1999). A subset of the IFN-induced intracellular pro-
eins, the Mx proteins, are responsible for antiviral activ-
ties against a number of negative-strand RNA viruses.
he murine nuclear Mx1 protein was shown to selec-
ively block influenza virus replication (Pavlovic et al.,
990; Staeheli et al., 1986), the rat Mx1 protein strongly
nhibited both influenza virus and vesicular stomatitis
irus (VSV), and rat Mx2 inhibited only VSV without af-
ecting influenza virus replication (Meier et al., 1990).
Human MxA is a 76-kDa protein that is induced to high
evels in the cytoplasm of type I IFN-treated human cells
nd was shown to have potent GTPase activity (Horis-
erger et al., 1990; Horisberger, 1992; Pitossi et al., 1993).
1 To whom reprint requests should be addressed. Fax: (301) 496-
t810. E-mail: atreyap@cber.fda.gov.
227onstitutive expression of human MxA in Swiss 3T3 cells
rotected these cells against challenge with influenza A,
SV, and Thogoto virus (Staeheli et al., 1986; Haller, 1993;
aller et al., 1995). Similarly, constitutive expression of
uman MxA inhibited replication of measles virus in the
uman monocytic cell line U937 (Schnorr et al., 1993) and
n U-87 glioblastoma cells (Schneider-Schaulies et al.,
994). MxA expression in U-87 cells also inhibited the
eplication of human parainfluenza type 3 (PIV3) (Zhao et
l., 1996). Likewise, expression of MxA in Vero cells
nhibited virus replication and infectious virus yields of
unta, Bunya, and Phlebo viruses (Kanerva et al., 1996;
rese et al., 1996). Based on these studies, it was gen-
rally accepted that Mx proteins exhibit antiviral activity
gainst negative-strand RNA viruses but not against pi-
ornaviruses with positive-strand RNA genome (Pavlovic
t al., 1990). However, a recent report indicates that
emliki forest virus (SFV), a Togavirus with a positive-
trand RNA genome, was also inhibited by MxA protein
xpressed in Hep-2 cells (Landis et al., 1998).
Respiratory syncytial virus (RSV) is the most important
ause of severe bronchiolitis and pneumonia in infants
nd children younger than 2 years. RSV infection could
e life threatening in children with certain predisposing
onditions (Collins et al., 1996). At present, there is no
icensed vaccine against RSV infection. It is estimated
hat 100,000 hospitalizations and 4500 deaths occur an-
0042-6822/99
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228 ATREYA AND KULKARNIually in the United States due to RSV infections (MMWR,
998). In the absence of an effective vaccine for RSV,
lternative treatments are being actively pursued (e.g.,
olyclonal antibodies, monoclonal antibodies, antisense
ucleotides, and viral inhibitors). IFNs and other cyto-
ines that augment intrinsic defenses of the lung against
SV would be of potential clinical benefit if the correct
FN subtypes, doses, and delivery routes needed for
ffective treatment were known.
The role of IFNs in RSV pathogenesis is controversial;
ome laboratory strains of RSV were reported to be
cutely sensitive to either nonviral IFN-inducers such as
oly(IC) or relatively impure preparations of IFNs (Hill et
l., 1969; Gardner et al., 1970). In contrast, during natural
nfection of children with RSV, very little or no IFN was
etected in nasal washes, suggesting that IFNs may not
ave a role in curbing RSV replication at the site of
nfection (Moehring et al., 1971; Hall et al., 1978, 1981;
cIntosh, 1978). Although some in vitro studies reported
FN production by RSV-infected peripheral blood mono-
ytes and in macrophages, others reported a lack of IFN
roduction in the same cells (Bell et al., 1983; Krilov et al.,
987; Roberts et al., 1992). One study reported that IFN
reatment of RSV-infected children does improve their
linical course, suggesting that exogenous IFN may aug-
ent intrinsic lung defense against this virus (Sung et al.,
993). In clinical trials with adult volunteers, recombinant
FN-2a was not proved to be very successful as a ther-
peutic agent against RSV, strain RSS-2 (Higgins et al.,
990). It is not known whether this particular IFN can, in
act, effectively decrease the replication and virus yield
f this specific RSV strain in vitro. As is true with other
iruses, different strains of RSV may have different de-
rees of sensitivity against a given type of IFN. Never-
heless, the apparent lack of clinical success of IFN as a
herapeutic agent against RSV has dampened interest in
sing cellular antiviral responses to combat RSV infec-
ions. Many viruses have developed mechanisms to sub-
ert early responses of the cellular IFN-mediated antivi-
al system (Smith, 1996; Krajcsi and Wold, 1998). The role
f RSV, if any, in counteracting early host defenses is
nknown. PIV3 is sensitive to the antiviral effects of MxA
rotein, either induced by exogenously added IFN-a or
xpressed in permanently transfected cells (Zhao et al.,
996).
In the present study, we compared the antiviral effects
f human type I IFNs (a or b) and IFN inducers [poly(IC)]
n replication of RSV strain A2 and PIV3 in either human
ung epithelial cells (A549) or fibroblast cells (MRC-5).
hese two cell types were selected because RSV infects
he lung epithelial lining and fibroblasts and hence may
ossess intrinsic mechanisms to restrict RSV replication
by induction of antiviral cytokines and IFNs) that might
ecome operative before the induction of specific im-
une responses. Furthermore, we tested whether MxArotein induced in these cells in response to IFN or Ixpressed constitutively in Vero or glioblastoma cells
an confer resistance to RSV strain A2, as was shown
efore with PIV3 (Zhao et al., 1996). We also tested
hether other antiviral proteins produced by IFNs pro-
ect the Hep-2 cells that do not express MxA protein
Melen et al., 1996) against RSV or PIV3. Finally, we
nvestigated whether RSV A2 or PIV3 can affect each
ther during coinfections in the absence or presence of
FNs. In this report, we demonstrate that although RSV
nd PIV3 belong to the same Paramyxoviridae family,
SV A2 possesses replicative strategies resistant to the
ntiviral effects of type I IFNs and MxA. To our knowl-
dge, this is the first report on the investigation of anti-
iral effects of MxA on RSV infection.
RESULTS
ffect of exogenously added type I IFNs on virus
roduction by RSV A2 in A549 or MRC-5 cells
As shown in Fig. 1A, exogenously added IFN-a or -b
xhibited only minor inhibitory effects on the yields of
nfectious RSV in A549 cells. Even at high doses of IFNs
5000–10,000 U/ml), virus yields were decreased to only
bout 5–10% of the IFN-untreated controls. In contrast,
nder the same conditions, yields of infectious PIV3
ere reduced significantly. At 10,000 U/ml dose of IFN-a
r -b, PIV3 yield was decreased to 0.1–0.01% of the
ntreated controls. Similar results were obtained using
RC-5 cells with both IFN-a -b (Fig. 1B). Compared with
549 cells, in MRC-5 cells the antiviral effects at lower
oses of IFNs appeared to be to slightly less pronounced
gainst PIV3, suggesting inherent cellular differences in
esponding to IFN treatment.
We also compared RSV A2 sensitivity with the antiviral
ffects of 1000 U/ml either IFN-a or -b in the cells (1)
reated for 20 h before the 2-h virus absorption and
nfection, (2) treated after the 2-h absorption and contin-
ed throughout thereafter, or (3) treated for 20 h before
s well as during the first 24 h or the entire infection
eriod. Results (data not shown) indicated that treat-
ents 1 and 3 resulted in 10- to 20-fold reduction in virus
ields compared with the untreated controls. Samples
rom treatment 2 resulted in virus yields essentially the
ame as the untreated controls. These results suggested
hat even the slight antiviral activity (10- to 20-fold reduc-
ion in yield) due to either of the IFNs observed against
SV A2 was seen only if the cells were pretreated with
FN-a or -b before infection but not after the infection
as initiated.
ffect of virus load on the antiviral activity of IFN-a
n A549 cells
We next tested whether the amount of virus load de-
ermines the extent of its sensitivity to a fixed amount of
FN-a. A549 cells were pretreated with 1000 U/ml of
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229RESISTANCE OF RSV A2 TO IFNs AND MxAFN-a and infected by either RSV A2 or PIV3 at 3 separate
ultiplicities of infection (m.o.i.) (i.e., 0.01, 0.1, or 1.0 PFU/
ell) and virus yields in the supernatants at 40 h postin-
ection (p.i.) were determined. Table 1 shows the repre-
entative data from a typical experiment. Even at the
owest virus RSV input (0.01 PFU/cell), virus yield in the
FN-treated sample decreased only to about 20-fold (1.3
og10 PFU/ml decrease) compared with the untreated
ample. A 10-fold increase in the virus inoculum (0.1
FU/cell) also resulted in a similar reduction (19-fold) in
irus yield. A further increase in virus inoculum (1.0 PFU/
ell) resulted in further increase in virus yield when
reated with IFN (only 8.5-fold reduction). These results
FIG. 1. Infectious virus yields of RSV A2 and PIV3 after pretreatment
f A549 (A) and MRC-5 (B) cells with 0–10,000 U/ml IFN-a or -b for 20 h,
ollowed by infection with the respective viruses at an m.o.i. of 0.1
FU/cell. The cells were harvested 40 h p.i., and the viruses in the
upernatants were titrated on Hep-2 cells. Infectious virus yield for
ach virus in IFN-treated samples at each dose was calculated as a
ercentage of the total virus yield, in PFU/ml, obtained in mock-treated
ontrol samples. Each point shown represents the mean percent virus
ield value obtained from at least three separate experiments, and the
ars show the standard deviation.ndicate that RSV A2, in general, is very resistant to thentiviral activity of a given amount of IFN-a regardless of
he virus load. In other words, 1000 U/ml IFN-a could not
ignificantly protect 1 3 106 A549 cells even when chal-
enged with low doses of RSV A2.
In contrast, PIV3 was found to be extremely sensitive
o IFN-a; at the lowest virus load tested (0.01 PFU/cell),
irus yield in the IFN-treated sample is decreased by as
uch as about 158,000-fold (5.2 log10 PFU) compared
ith untreated sample. A 10-fold increase in the virus
noculum (0.1 PFU/cell) resulted in a 10,000-fold (4 log10
FU) decrease in virus yield in IFN-treated sample. At the
ighest m.o.i. tested (1 PFU/cell), the virus yield in IFN-
reated sample was decreased by only about 472-fold
2.7 log10 PFU) compared with the untreated sample.
ven this level of reduction in PIV3 virus yield is signifi-
ant compared with RSV A2 under similar conditions
compare 472-fold with 8.5-fold reduction, respectively).
hese results suggest that IFN-a may be extremely ef-
ective against low amounts of PIV3 virus but that a high
irus load can overcome the antiviral activity of a given
mount of IFN-a.
ffect of IFN inducers on RSV A2 virus yields
n A549 cells
To rule out the possibility that IFN induced from
ithin the same cells somehow would be more effec-
ive than exogenously added IFN, we treated A549
ells with known IFN inducers such as poly(IC) alone
simple induction) or in combination with DEAE-dex-
ran (super induction) and evaluated their effects on
he infectious virus production by either RSV A2 or
IV3. As shown in Fig. 2A, the treatment of A549 cells
ith increasing amounts of poly(IC) in the absence or
resence of DEAE-dextran did not inhibit infectious
SV A2 virus production significantly (a decrease to
–10% of the untreated controls). Under the same
onditions, infectious PIV3 virus yield is drastically
TABLE 1
Effect of Virus Load on the Antiviral Activity of 1000 U/ml IFN-a
in 1 3 106 A549 Cells
Virus Yeild (PFU/ml)
Virus
m.o.i.
(PFU/cell) 2IFN 1IFN
Fold reduction
in virus yielda
SV 0.01 3.1 3 105 0.15 3 105 20
SV 0.1 24 3 105 1.29 3 105 19
SV 1.0 57 3 105 6.7 3 105 8.5
IV3 0.01 84 3 107 53 3 102 158,490
IV3 0.1 83 3 107 80 3 103 10,375
IV3 1.0 51 3 107 105 3 104 472
Note. Data from a representative experiment, with each treatment
one in triplicate; the average value is shown.a Fold reduction 5 virus yield (2IFN)/virus yeild (1IFN).
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230 ATREYA AND KULKARNIecreased (to 0.01–0.001% of the untreated controls).
igure 2B shows that RSV-specific protein synthesis
as not affected by poly(IC) treatment. We directly
easured the amount of IFNs produced in these and
ther experiments (data not shown) and found that
oly(IC) alone induced 100 U/ml and that poly(IC) plus
EAE-dextran induced 1000–2000 U/ml of antiviral ac-
ivity, respectively, in A549 cells. These results, there-
ore, suggested that in A549 cells, (1) poly(IC) either
lone or in combination with DEAE-dextran induced
FNs with antiviral activity, (2) these IFNs are effective
FIG. 2. Effects of poly(IC) alone (simple induction) or in combination
r PIV3 and (B) RSV A2 viral protein expression. A549 cells were pretrea
or 20 h followed by infection at an m.o.i. of 0.1 PFU/cell for 40 h. Supe
nfectious virus yields (A) were calculated as described. Data represe
xperiments, and the bars show the standard deviation. Western blo
ntibodies (at 1:1000 dilution) shows that viral protein synthesis was no
efore infection.gainst PIV3, and (3) RSV A2 infection somehow was 1esistant to the antiviral effects of these internally
nduced IFNs also.
ffects of type I IFNs on induction of antiviral MxA
nd translation of RSV proteins
We tested whether (1) antiviral MxA protein is ex-
ressed in MRC-5 and A549 cells in response to type I
FNs and (2) type I IFNs have any effect on RSV A2-
pecific protein synthesis. In these experiments, MRC-5
ells were either mock treated or treated with 100, 500, or
EAE-dextran (super induction) on infectious virus yields of (A) RSV A2
h 0–100 mg/ml poly(IC) alone or mixed with 100 mg/ml of DEAE-dextran
t samples were harvested, collected, and titrated on Hep-2 cells, and
mean percent virus yield value obtained from at least three separate
sis (B) of total cellular proteins using RSV-specific rabbit polyclonal
ed by treating the cells with increasing amounts of poly(IC) (lanes 2–6)with D
ted wit
rnatan
nt the
t analy
t affect000 U/ml IFN-a or -b for 20 h and then infected with RSV
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231RESISTANCE OF RSV A2 TO IFNs AND MxA2. At 20 h p.i., cells were harvested and total cell lysates
ere prepared, separated by SDS–PAGE, and analyzed
y Western blots using MxA- and RSV-specific antisera.
xA protein was found to be produced in a dose-specific
esponse to either IFN-a or -b, respectively (Fig. 3, top,
anes 1–8). This result clearly indicates that MRC-5 cells
ere able to respond to type I IFNs and that antiviral
roteins were made. However, RSV A2 viral protein syn-
hesis did not decrease significantly under these condi-
ions. As shown in Fig. 3, bottom, the levels of RSV-
pecific proteins were identical in mock-treated (lane 2)
nd IFN-treated (lanes 3–8) samples. Similar results ob-
ained with A549 cells (data not shown) indicated that the
bserved resistance of RSV A2 to type I IFNs is not cell
ype specific or due to a general defect in the IFN
athway in these cells.
roduction of infectious RSV A2 in MxA protein
xpressing cell lines
We next directly tested whether cells stably express-
ng human MxA protein are resistant to infection by RSV
2 or PIV3. We used two separate cell lines, of human or
imian origin transfected with a human MxA gene, that
onstitutively expresses MxA protein in the presence of
he drug G418 (Schneider-Schaulies et al., 1994; Haller et
l., 1993; Zhao et al., 1996; Kanerva et al., 1996; Frese et
l., 1996). In these cells, infectious RSV or PIV3 yields
ere compared at two virus loads (0.1 or 1.0 PFU/cell),
nd cell supernatants were harvested at 24, 48, 72, or
6 h p.i. in both cases to compare them at different
tages after multiple rounds of replication.
Figure 4A shows the expression of MxA protein in
tably transfected cells VA-9 and U-87-H4 and lack of its
FIG. 3. Western blot analysis of proteins synthesized in MRC-5 cells
00 (lane 4) or 1000 (lane 5) U/ml IFN-a or 100 (lane 6), 500 (lane 7), or
or 20 h (lanes 2–8). One blot was reacted with rabbit polyclonal antibod
ntibody against RSV A2 (both at 1:1000 dilution), as described in the t
arkers, BioRad) are indicated to the left; MxA protein and RSV nuclexpression in the parent cells VN-5 and U-87-CL4. As Ieen in Fig. 4A, slightly less MxA was produced in
-87-H4 compared with VA-9 cells. The infectious virus
ields of RSV A2 and PIV3 in these cell lines at 0.1 and 1.0
FU/cell after 24 h of infection are shown in Fig. 4B.
xA-expressing cells (VA-9 and H-4) were not resistant
o the infection by RSV A2 compared with the cells
acking the MxA protein (VN-5 and H-4). This is evident
y the similar amounts of infectious virus produced by
SV A2 in both MxA-expressing and -nonexpressing
ells. This result was consistently observed regardless
f the dose of the virus inoculum (0.1 and 1.0 PFU/cell) or
uration of total infection [i.e., 24 h (Fig. 4B), 48 h, 72 h,
r 96 h (data not shown)]. In contrast, multiplication of
IV3 was reduced by 100- to 500-fold in MxA-expressing
ells, especially at the lower doses of inoculum and
hen the infection was carried out for 24 h. At higher
.o.i. or when infection was carried out for longer peri-
ds of time (i.e., up to 72 or 96 h), the amount of infec-
ious PIV3 produced in MxA-expressing cells was not
ignificantly different from that obtained in MxA-nonex-
ressing cells (data not shown).
ffect of type I IFNs on RSV A2 and PIV3 in Hep-2
ells that do not express MxA protein
IFNs induce a number of antiviral proteins in host cells
n addition to MxA protein (Staheli, 1990; Samuel, 1991).
e therefore investigated the antiviral effects of type I
FNs against both RSV A2 and PIV3 in Hep-2 cells, which
o not express MxA protein (Melen et al., 1996) but may
ave other IFN-induced antiviral proteins. The experi-
ents were carried out under identical conditions of IFN
reatments in either Hep-2 or A549 cells. Figure 5A
hows the Western blot analysis of MxA expression in
ad been left untreated (lanes 1 and 2) or pretreated with 100 (lane 3),
ne 8) U/ml IFN-b and infected with RSV A2 at an m.o.i. of 0.1 PFU/cell
st human MxA, and a duplicate blot was reacted with rabbit polyclonal
e positions and molecular masses (M) of marker proteins (prestained
protein N and phosphoprotein P are indicated to the right.that h
1000 (la
y again
ext. ThFN-treated A549 cells and its absence in IFN-treated
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232 ATREYA AND KULKARNIep-2 cells using highly specific anti-MxA antibodies
rom which cross-reacting antibodies against MxB were
emoved. The use of these specific antibodies was nec-
ssary because IFN can induce MxB in Hep-2 cells
Melen et al., 1996).
Figure 5B shows results of the antiviral effects of IFN-a
n RSV A2 or PIV3 in Hep-2 or A549 cells from a repre-
entative experiment. The virus yield of RSV A2 in either
ell line was greater than 10% of the control, suggesting
hat RSV A2 was also resistant to other IFN-induced
ntiviral proteins. As expected, PIV3 yield was reduced
o 0.5–0.1% of the untreated control in A549 cells that
xpress MxA protein. In Hep-2 cells that do not produce
xA protein, PIV3 yield was less inhibited (5% of the
ntreated controls) but still more sensitive to IFN than
SV A2. Therefore, in cells that do not express MxA,
ntiviral effects of IFN-a may be mediated by other IFN-
FIG. 4. Western immunoblot analysis (A) of MxA protein expression i
xpress MxA, but VA-9 and H-4 samples (lanes 5 and 9) express MxA pr
rotein molecular mass marker (80 kDa), M. Lanes 2, 4, 6, and 8 wer
pecific for human MxA was used as the probing antibody (1:1000 diluti
nd nonexpressing cells. About 1 3 106 cells of each type were infecte
ells were harvested, and supernatants collected and titrated on Hep-
ere calculated as a percentage of the yields obtained in VN-5 or CLnduced antiviral proteins in inhibiting PIV3 multiplica- cion, although the inhibition was not as effective as that
n the cells that express MxA.
ffect of IFN-resistant RSV A2 on IFN-sensitive PIV3
uring coinfection
The observed resistance of RSV A2 to the effects of
ype I IFNs may be due to disruption of the cellular
ntiviral state by RSV infection such that RSV A2 repli-
ation and production of infectious progeny are not in-
ibited. This disruption may be mediated by factors se-
reted into the culture medium by RSV-infected cells or
nduced within the RSV-infected cells. To test the possi-
ility that RSV disrupted the cellular antiviral responses,
e sought to determine the consequences of coinfection
ith both IFN-resistant RSV and IFN-sensitive PIV3 on
IV3 replication in IFN-treated cells. If RSV disrupted the
y transfected cell lines. VN-5 and CL-4 samples (lanes 3 and 7) do not
ach sample contained about 20 mg of protein. Lane 1 contains BioRad
y lanes that received only sample buffer. Polyclonal rabbit antiserum
Infectious virus yields of RSV and PIV3 obtained from MxA expressing
SV A2 or PIV3 at an m.o.i. of 0.1 or 1.0 PFU/cell. After 24 h of infection,
Infectious virus yields for each treatment in VA-9 or H-4 (MxA1) cells
2) cells as the controls, respectively.n stabl
otein. E
e empt
on). (B)
d with R
2 cells.
-4 (MxAellular antiviral responses, then PIV3 replication should
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233RESISTANCE OF RSV A2 TO IFNs AND MxAe spared from antiviral effects of IFNs. The results of
hese experiments are described in Fig. 6 and Table 2.
Figures 6A–6D, left, show the data from samples in the
bsence of IFNs, and Figs. 6F–6I show data from sam-
les treated with 1000 U/ml IFN-a. When RSV- or PIV3-
nfected monolayers were tested with virus-specific
onoclonal antibodies (MAbs), very clear cytopathic ef-
ects (CPEs) characteristic of RSV and PIV3, respectively,
ere seen (Figs. 6A and 6B). This indicates ongoing
nfection and replication of RSV or PIV3 in these mono-
ayers in the absence of externally added IFN-a. In these
nd other experiments, PIV3-specific large CPEs devel-
ped much faster (within 48 h) and are very distinct and
isible under light microscope without the aid of any
hromogenic reagents. Therefore, the use of PIV3-spe-
FIG. 5. Western immunoblot analysis (A) showing MxA protein expre
n Hep-2 cells. Lane 1 indicates BioRad protein molecular mass mark
epresent 100 U/ml IFN-treated samples. Lanes 4 and 7 represent 1000
onstitutively expresses MxA protein and serves as a positive control. E
ighly specific against human MxA was used as the probing antibod
FN-a-treated (at indicated doses) A549 and Hep-2 cells. Cells were in
arvested at 40 h p.i. and titrated on Hep-2 cells.ific MAbs provides additional supporting evidence for ohe PIV3-specificity of the observed CPEs (Fig. 6B). Un-
er similar conditions, RSV A2 takes much longer to
how clear CPEs (5–8 days) and the need for RSV-
pecific MAbs is warranted to identify, as well as to
stablish the specificity of the small RSV-specific CPEs
n the monolayers (Fig. 6A). Figure 6C shows the coin-
ected culture in the absence of IFN-a and the cells were
reated with RSV MAbs; both RSV-specific small CPEs
arrowheads) and large, clear, unstained CPEs charac-
eristic of PIV3 (boxed area) are separate, indicating the
ells that were singly infected with either RSV or PIV3. In
ddition, some large, rounded PIV3 like CPEs but stained
ositive with RSV-specific MAbs are seen (arrows), sug-
esting that they were doubly infected with both RSV and
IV3. A PIV3-specific CPE that was devoid of stain on
y treatment with 100 or 1000 U/ml IFN-a in A549 cells and its absence
Da). Lanes 2 and 5 represent mock-treated samples. Lanes 3 and 6
FN-treated samples. Lane 8 represents an uninfected H-4 sample that
ple contained about 20 mg of protein. Polyclonal guinea pig antiserum
0 dilution). (B) Infectious virus yields of RSV and PIV3 obtained from
with each virus at an m.o.i. of 0.1 PFU/cell, and the supernatants weression b
er (80 k
U/ml I
ach sam
y (1:10
fectedne side but stained positive for RSV proteins on another
c
P
234 ATREYA AND KULKARNIFIG. 6. Indirect immunocytochemistry on A549 cell monolayers showing the effects of IFN-a on RSV A2 and PIV3 in single or coinfections. A549
ells (1 3 106) were either mock-treated or treated with 1000 U/ml IFN-a for 20 h followed by 2-h adsorption with RSV A2 (2500 PFU) or PIV3 (500
FU) alone or together in 1-ml volume. Infected monolayers were incubated under 1% methyl cellulose overlay medium for 48 h at 37°C. When
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235RESISTANCE OF RSV A2 TO IFNs AND MxAide (highlighted asterisk) is also seen. Figure 6D shows
duplicate monolayer coinfected with RSV A2 and PIV3
ut treated with PIV3-specific MAbs where large,
ounded PIV3-specific CPEs stained positive for PIV3
roteins are seen. Note the CPE indicated by the arrow
n Fig. 6D that reacted positive with PIV3 MAb is very
imilar to the doubly infected CPE shown by the arrow in
ig. 6C. However, no small RSV-specific CPEs were seen
n these coinfected cells.
When treated with IFN-a, RSV-infected cells still de-
eloped characteristic CPEs, although the numbers were
lightly reduced (Fig. 6F and Table 2), but in IFN-treated
IV3-infected monolayer, all the distinctive PIV3-specific
PEs were totally absent as expected. Occasionally, in
nly some experiments, up to five lightly stained individ-
al cells (of 1 3 106 cells) were seen (Fig. 6G). Except for
his very light staining indicating a positive reaction for
IV3 proteins, these cells do not resemble typical PIV3-
pecific CPEs. Because they were not observed consis-
ently in most experiments, they were not considered to
e very significant. This is in stark contrast to the hun-
reds of PIV3-specific CPEs seen in IFN-untreated cells
Fig. 6B). When IFN-treated, coinfected cells were tested
IV-3-specific CPEs were visible, cells were fixed, blocked in 5% (w/v) no
r PIV3- (HN protein) specific MAbs. The monolayers were washed a
nzyme. Color development was done with Sigma Fast diaminobenz
ntreated, mock-infected cell monolayers probed with anti-RSV and
ninfected cell monolayers. (A and F) RSV A2-infected monolayers prob
IV3-specific MAb. (C and H) Monolayers coinfected with both RSV A2 a
ith both RSV A2 and PIV3 but probed with PIV3-specific MAb. (C) Arrow
hows colorless PIV3-specific CPEs that did not stain with RSV-specific
SV-specific MAb indicating doubly infected cells. The highlighted aste
ith RSV-specific MAb on the other side. (D) Arrow indicates the large P
T
Effect of IFN-a (1000 U/ml) on RSV-A2-and P
reatment Infecting virus
Specificity of the
primary MAb
1 RSV A2 RSV G, F
2 PIV3 PIV3 HN
3 RSV A2 1 PIV3 RSV G, F
4 RSV A2 1 PIV3 PIV3 HN
5 No virus RSV G, F
6 No virus PIV3 HN
7 RSV A2 PIV3 HN
8 PIV3 RSV G, F
Note. Cumulative data from three separate experiments; in each ex
a RSV-specific small CPEs (Fig. 6A); data represent mean 6 S.D.
b PIV3-specific large CPEs (Fig. 6B); data represent Mean 6 S.D.
c PIV3-specific large CPEs but stained positive with RSV-specific MA
d Fold reduction in CPE5 No. of CPEs (2IFN)/No. of CPEs 1IFN.Ab, confirming the doubly infected nature of such CPEs. Images shown weith RSV MAbs, the small RSV-specific CPEs were ob-
erved (Fig. 6H) similar to those observed in single RSV
nfection experiments (Fig. 6F). However, there were no
IV3-specific CPEs in the monolayer. Even the PIV3-like
PEs that stained positive with RSV MAbs in the ab-
ence of IFN-a (Fig. 6C, arrows) were totally absent in
FN-treated coinfections (Fig. 6H). These results suggest
hat coinfection with RSV did not prevent the IFN-medi-
ted inhibition of PIV3 replication and CPE formation.
his is further confirmed in duplicate sets of IFN-treated,
oinfected monolayers that were tested with PIV3-spe-
ific MAbs where PIV3-specific CPEs completely disap-
eared and the single, lightly stained cell was seen only
nce in six to eight separate experiments (Fig. 6I). A
omparison of the data in Fig. 6B with Fig. 6G and that in
ig. 6D with Fig. 6I indicates that IFN-a was able to
nhibit PIV3 replication and CPE formation in both single
nfections and coinfections, respectively. Even if when
he infection time was further extended to 72 h, allowing
he slow-growing plaques to be detected, no PIV3-spe-
ific or “hybrid” (doubly infected) CPEs were observed.
Table 2 presents the quantification of the above re-
ults. In the absence of IFN, the total number of RSV-
y milk in TTBS, and treated overnight with either RSV- (G and F protein)
ted with goat anti-mouse IgG conjugated to horseradish peroxidase
ubstrate. (A–E) Mock-treated cells. (F–I) IFN-treated cells. (E and J)
V3 MAbs, respectively, showing lack of reactivity of the MAbs with
RSV-specific MAbs. (B and G) PIV3-infected monolayers probed with
3 and probed with RSV-specific MAbs. (D and I) Monolayers coinfected
indicate small RSV-specific CPEs similar to those in A; the boxed area
and the arrows points to PIV3-specific CPEs that stained positive with
ws a PIV3-specific CPE partly clear on one side while stained positive
cific CPE similar to the one in C but stained positive with PIV3-specific
cific CPEs during Coinfection in A549 Cells
No. of CPEs/well
2IFN 1IFN
Fold reduction
in CPEsd
2093 6 612a 467 6 180a 4.6 6 0.5
385 6 87b 0 Complete
1800 6 148a 447 6 148a 4.3 6 1.1
185 6 75c 0 Complete
325 6 25b 0 Complete
None None
None None
None None
None None
t, each treatment was done in duplicate or triplicate wells.
6C, arrow); data represent Mean 6 S.D.nfat dr
nd trea
oate s
anti-PI
ed with
nd PIV
heads
MAb,
risk sho
IV3- speABLE 2
IV3-Spe
perimen
b (Fig.re at 403 magnification.
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236 ATREYA AND KULKARNIpecific CPEs in both single (treatment 1) and coinfec-
ions (treatment 3) were almost the same, suggesting
hat infection by PIV3 did not preclude the infection and
eplication of RSV. Similarly, the number of PIV3-specific
PEs in single (treatment 2) and coinfections (treatment
) were almost the same, indicating that infection by RSV
id not prevent the infection by PIV3. The presence of
hybrid” CPEs also indicates that these viral infections
ere not mutually exclusive. With 1000 U/ml IFN-a, in
oth single and coinfections, there was only about a 4- to
-fold decrease in RSV-specific CPEs compared with
ntreated controls. Hence, RSV was not very sensitive to
he added IFN, and even in coinfections, the presence of
IV3 did not make RSV more sensitive to the antiviral
ffects of IFN-a. The number of PIV3-like CPEs that
tained positive with RSV A2 MAb (doubly infected CPEs)
n coinfections (treatment 3) represents about 10% of the
otal RSV CPEs that were totally absent in IFN-treated
onolayers.
PIV3 was acutely sensitive to IFN-a, in both single or
oinfections, and no PIV3-specific CPEs were seen in
FN-a-treated cells. This demonstrates that the presence
f IFN-resistant RSV A2 in the same cell did not prevent
he IFN-mediated inhibition of PIV3 growth and multipli-
ation. Similar to mock-treated cell monolayers, it is
ossible for some cells (about 10%) to be infected by
oth viruses even in the IFN-treated monolayers be-
ause IFN-a does not prevent infection of the cells by
IV3 but acts at a later stage of infection (Zhao et al.,
996). However in IFN-treated coinfected monolayers, no
oubly infected cells (PIV3-specific CPEs and positive for
SV antigen) were seen, probably because PIV3 replica-
ion continued to be inhibited by a cellular antiviral mech-
nism that remains active even in the presence of RSV
eplication.
DISCUSSION
RSV replicates in both MRC-5 and A549 cells (McKay
t al., 1988; Merolla et al., 1995). In this study, we dem-
nstrated only a minor reduction in viral yield (Fig. 1) and
lack of reduction in viral protein synthesis (Fig. 3) when
SV A2 replicated in IFN-treated human lung fibroblasts
MRC-5) or the human lung alveolar epithelial cell line
A549) compared with IFN-untreated cells. This interpre-
ation was based on the fact that many viruses consid-
red highly sensitive to IFN (e.g., VSV, HSV, PIV3) gener-
lly exhibited at least a 100-fold decrease in their yields
f infectious virus (Belkowski and Sen, 1987; Zerial et al.,
982; Zhao et al., 1996). Earlier studies considered a 50%
2-fold) reduction in RSV yield to be significant (Gardner
t al., 1970; Hall et al., 1978). Studies that reported RSV
ensitivity to 5 or 2.5 U of human leukocyte IFN (1.5 log10
eduction in titter) used the Long strain of RSV, tested in
rimary Patas monkey kidney cells (Gardner et al., 1970).n our hands, the Long strain was not more sensitive fhan RSV A2 to any dose (10–10,000 U/ml) of IFN-a or -b
hen tested in A549 cells (P. L. Atreya, unpublished
ata). This lack of inhibition of RSV A2 in response to
FNs was not dependent on the source of IFN, either
xternally added (Fig. 1) or internally induced (Fig. 2) by
FN inducers such as poly(IC). Under these conditions,
ntiviral protein MxA was induced and expressed in a
ose-dependent manner in response to both IFN-a or -b,
ndicating that at least this pathway of the antiviral state
as clearly established in both A549 and MRC-5 cells.
urthermore, this established antiviral state appears
unctional because infectious virus yields of PIV3 were
rastically reduced under these conditions, as was re-
orted earlier by Zhao et al. (1996).
In preliminary experiments, we tested whether the
mounts of (10–10,000 U/ml) various IFNs (a or b) used
n these experiments were toxic to A549, MRC-5, or
ep-2 cells by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
yltetrazolium (MTT) cytotoxicity assays. Results of these
xperiments indicated that even at the highest amounts
f IFN (i.e., 10,000 U/ml), IFN-treated cells were metabol-
cally as viable as the untreated cells (within 10–15% of
he control; data not shown). Hence any inhibitory effects
bserved in our experiments were not due to nonspecific
ffects of cellular toxicity induced by IFNs.
Even the slight reduction in virus yields of RSV A2 in
FN-treated samples was observed only if IFN treatment
ccurred before infection but not after the infection was
nitiated. The reductions in virus yields of samples sub-
ected to a combination of preinfection and p.i. IFN treat-
ent were essentially the same as the reduction in virus
ields of samples, only pretreated with IFNs. Based on
his, we cannot rule out the possibility that the initial
nfection of RSV may have been slightly inhibited in the
ells treated with IFN before infection. Once RSV infec-
ion was initiated, IFNs did not seem have any effect on
ubsequent rounds of virus replication and burst size.
nalysis of the effect of IFN on RSV infection described
n Figs. 6A and 6F and Table 2 also seems to support this
ossibility. Here, the total number of RSV-infected cells
as decreased sufficiently (;5-fold) by pretreatment of
he cells with IFN-a (Fig. 6F) to account for the reduction
n their titer. However, it remains to be determined how
he initial infection of RSV A2, if at all, may be inhibited by
retreatment of the cells with IFN-a.
We directly compared the sensitivity of PIV3 and RSV
2 to a given amount of IFN-a at three separate viral
oads. This type of comparison is perhaps useful in
etermining the effective dose of IFNs against specific
iruses. Our results (Table 1) show that IFN-a was ex-
remely effective against a low dose of PIV3 but that at a
igher PIV3 load, the antiviral activity of a given amount
f IFN-a may become ineffective. This result indicates
ome sort of a direct, dose-dependent interaction be-
ween PIV3 viral components and IFN-induced antiviral
actors that might become saturated at higher viral loads.
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237RESISTANCE OF RSV A2 TO IFNs AND MxAn contrast, even at a low virus dose, RSV seems rela-
ively insensitive to the antiviral effects of IFN-a. A 10- or
00-fold increase in virus loads did not significantly
hange the level of sensitivity to IFN any further, sug-
esting that there may not be a direct, dose-dependent
nteraction between viral components and IFN-induced
ntiviral factors.
Cells lacking MxA protein produced similar amounts
f infectious virus yields of RSV A2 compared with cells
hat do express MxA (Fig. 4), demonstrating that the
xpression of MxA did not affect RSV A2 replication. This
as observed in two separate cell lines, of human or
imian origin, indicating that the observed effects are
pecific to the virus rather than to the cell type. In con-
rast, in both types of MxA-expressing cells, 100- to
00-fold less infectious PIV3 was produced, suggesting
hat the presence of MxA inhibited PIV3 replication. How-
ver, with increasing virus loads as would be expected in
xtended incubation periods due to multiple rounds of
nfection, the protection offered to the cells by constitu-
ively expressed MxA appeared to decrease. Previously,
hao et al. (1996) also reported that PIV3 virus yields
ere less inhibited in MxA expressing H4 cells at higher
.o.i. (10 PFU/cell) compared with lower m.o.i. (1 PFU/
ell or less).
Because many antiviral proteins are induced in re-
ponse to IFN in addition to MxA (Staheli, 1990, Samuel,
991), we tested whether in the absence of MxA other
FN-induced antiviral proteins can confer resistance to
SV or PIV3. We found that in IFN-treated Hep-2 cells
hat do not express MxA (Melen et al., 1996), although
SV infection was not significantly affected, PIV3 virus
ields were still diminished, although to a lower extent,
ompared with the yields in IFN-treated A549 cells that
xpress MxA protein (Fig. 5). Hence, PIV3 replication
ay be independently inhibited by MxA and other IFN-
nduced antiviral proteins. However, cumulative effects of
xA and other antiviral proteins may be much more
ffective against PIV3. Our results lead to similar conclu-
ions as those drawn by Zhao et al. (1996), although they
sed the IFN-treated U-87 parent cell line to test the
ffects of other antiviral proteins against PIV3. Zhao et al.
1996) reported that in MxA-expressing cells, although
IV3 replication was decreased by more than 100-fold
ith concomitant viral RNA synthesis by 80%, primary
iral transcription was not affected. In contrast, in the
arent U-87 cell line, IFN-mediated inhibition occurred at
he primary transcription of PIV3 replication. These data
uggested that in addition to MxA, other IFN-inducible
ntiviral proteins are effective against PIV3 in both the
ell lines.
We did not characterize the other IFN-responsive an-
iviral proteins induced in Hep-2 cells in this report. In
ddition to MxA, two other best-characterized antiviral
echanisms are known to exist in many cell types: (1)ouble-stranded (ds)RNA-dependent protein kinase Rnd (2) dsRNA-dependent 29,59-A activated RNase L. The
ormer enzyme is known to mediate antiviral effects by
nhibiting host cellular and viral protein synthesis
hrough phosphorylation of the translation factor eIF2
nd the latter enzyme by the dsRNA-induced breakdown
f single-stranded viral and cellular RNA. Although we
id not directly measure the activities of protein kinase R
r RNase L enzymes in IFN-treated A549 cells, it is
ossible that RSV A2 replication also may be resistant to
hese antiviral mechanisms. Evidence for this suggestion
omes from the observation that both RSV protein syn-
hesis (Fig. 3) and viral RNA levels (data not shown) were
ot significantly decreased by prior IFN treatment. Direct
esting of these enzyme activities in IFN-treated, RSV-
nfected cells is needed to further verify these hypothe-
es.
Previously, it was shown that another IFN-resistant
irus, human adenovirus Ad5, not only replicated effi-
iently in A549 cells in the presence of IFN-a but also
revented the IFN-mediated inhibition of VSV replication
Anderson and Fennie, 1987). Adenovirus early region
1A-encoded product interferes with transcriptional sig-
aling process of IFN, thus blocking the effects of IFN
Leonard and Sen, 1997), and thereby blocks the cellular
esponse that inhibits VSV replication. In the present
tudy, we investigated whether IFN-resistant RSV A2
ould offer similar protection to highly IFN-sensitive PIV3
hen A549 cells were coinfected simultaneously with
oth viruses in the presence of IFN-a. We hypothesized
hat if the apparent resistance of RSV A2 to IFN-a was
ue to the inactivation of IFN-induced antiviral state by
SV infection [either by induction of soluble factors re-
eased into the medium or within the RSV-infected cells
y interfering with IFN-stimulated gene (ISG) expres-
ion], then PIV3 multiplication in the coinfected cell cul-
ure should also be spared from the antiviral effects of
FN-a.
Our data (Fig. 6 and Table 2) clearly demonstrate that
lthough the number of RSV-infected cells were slightly
ecreased (Fig. 6F; probably due to the slight inhibition
f initial infection), viral replication in IFN-treated, RSV
2-infected cells seemed to proceed normally as indi-
ated by the RSV-specific CPEs similar to those ob-
erved in untreated cells. A similar number of RSV-in-
ected cells were seen in IFN-treated, coinfected cul-
ures (Fig. 6H). The continued IFN-resistant replication of
SV A2 in the coculture did not, however, protect PIV3
rom the antiviral effects of IFN-a. One possibility is that
he resistance of RSV A2 to IFN-a may not have been
ediated by soluble factors released into the medium by
SV-infected cells. In addition, even within the same
ells that are coinfected with both viruses, PIV3 was not
pared from the inhibitory effects of IFN, suggesting that
he established antiviral state was still functional and
ffective against PIV3.RSV A2 infection may not be actively disrupting the
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238 ATREYA AND KULKARNIntiviral ISG expression and their activity. We speculate
hat the apparent resistance of RSV A2 replication to
FN-a may be due to insensitivity of the viral polymerase
o ISGs and antiviral proteins in the presence of a viral
actor or factors rather than the active disruption of IFN-
timulated antiviral state. There are at least three RSV
roteins whose functions are not clearly defined and
robably could have a role in protecting RSV replication
rom the antiviral host response. These proteins probably
re absent during initial infection, making it somewhat
ulnerable, but are produced once the infection is initi-
ted and subsequent rounds of transcription and trans-
ation take place. We have recently shown that NS1, one
f the RSV nonstructural proteins, has potent negative
egulatory effects on viral replication and transcription in
RSV model minigenome system (Atreya et al., 1998).
S2, another RSV nonstructural protein, seem to have
imilar inhibitory effects on viral polymerase in a mini-
enome system, but compared with NS1, much higher
mounts of NS2 were needed for such inhibitory effects
P. Atreya and P. Collins, unpublished data). A small
ydrophobic protein of RSV is produced in RSV-infected
ells that is also known to be present in the virions; the
unction of this protein also is not yet clearly defined. In
ddition, an internal open reading frame (ORF-2) of the
2 protein of RSV has been reported to have a role in
nhibiting the RSV minigenome transcription and replica-
ion (Collins et al., 1996a), but it may have other functions
n vivo. Some of the recently described natural mutants
r the recombinant RS viruses lacking the small hydro-
hobic and other viral proteins seemed to exhibit altered
rowth properties and plaque morphology compared
ith wild-type RSV A2 (Karron et al., 1997, Bukreyev et al.,
997, Teng and Collins, 1999). Further investigation of
uch deletion mutants of RSV for their sensitivity to IFNs
ay indicate whether some of these viral proteins have
role in protecting viral replication from the antiviral
ffects of IFNs.
MATERIALS AND METHODS
ell lines, viruses, IFNs, and antibodies
Human lung epithelial carcinoma cells (A549, ATCC,
CL-185), human lung fibroblast cells (MRC-5, ATCC,
CL-171), human epidermoid laryngeal carcinoma cells
HEp-2, ATCC, CCL-23), and PIV3 strain 243 (ATCC, VR-
3) were purchased from American Type Culture Collec-
ion (Manassas, VA). Human IFN-a (I-2396) and -b (I-
640) were purchased from Sigma Chemical Co. (St.
ouis, MO) and diluted further in E-MEM containing 1%
CS, 2 mM L-Gln, and antibiotic and antifungal supple-
ents (1% GASP and 2.5 mg/ml amphotericin B; Quality
iologicals, MD) before treatment of the cells. Poly(IC)
as from Pharmacia Biochemicals (Piscataway, NJ), and
EAE-dextran was from ICN Biochemicals (Costa Mesa,
A). All the cell lines were maintained in E-MEM with m0% FCS and the above-mentioned antibiotic and anti-
ungal supplements. An initial inoculum of RSV A2 and a
ouse monoclonal antibody against PIV3 hemagglutinin
ere provided by Dr. Judy Beeler (CBER, FDA). Both RSV
nd PIV3 stocks were prepared in Hep-2 cells and ti-
rated in Hep-2 cells by plaque assay.
Vero cell clones expressing (VA-9) or not expressing
uman MxA protein (VN-5) and human glioblastoma cell
lones expressing (U-87-H4) or not expressing human
xA protein (U-87-CL4) were described previously
Haller et al., 1993; Schneider-Schaulies et al., 1994; Zhao
t al., 1996). The guinea pig polyclonal antibodies highly
pecific for human MxA (antibodies cross-reacting with
xB were removed by adsorbing the MxA antibodies to
ixed and permeabilized recombinant baculovirus-in-
ected cells expressing human MxB; Melen et al., 1996)
nd mouse monoclonal antibodies against RSV N, P, G,
nd F were described previously (Garcia-Barreno et al.,
989; 1996). Polyclonal antiserum against RSV proteins
as prepared in New Zealand White rabbits at the Divi-
ion of Veterinary Services (CBER, FDA). Glioblastoma
ells expressing MxA were maintained in E-MEM con-
aining 10% FCS and antibiotic and antifungal supple-
ents as mentioned and 0.5 mg/ml G418 (GIBCO-BRL,
ockville, MD). Vero cells expressing Mx A were main-
ained in DMEM with 10% FCS and antibiotic and anti-
ungal supplements as indicated and 1 mg/ml G418.
etermination of effects of IFNs or IFN inducers on
irus yields
The effects of externally added IFN-a or -b (0–10,000
/ml) on infectious RSV A2 and PIV3 were tested in
0–80% confluent monolayers of either A549 or MRC-5
ells in 6-well culture dishes. Approximately 1 3 106
ells/well were pretreated with indicated doses of IFN
or 20 h and then infected with either RSV A2 or PIV3 at
.1 PFU/cell m.o.i. except where indicated otherwise.
To analyze the effects of endogenously produced
FNs, cells were pretreated for 20 h with IFN inducers
uch as poly(IC) alone (0–100 mg/ml) or in combination
ith DEAE-dextran (100 mg/ml) and then infected with
ither RSV or PIV3 at 0.1 PFU/cell. Virus was adsorbed to
he cells for 2 h, the inoculum was removed, and mono-
ayers were washed twice with E-MEM containing 1%
CS and other antibiotic and antifungal supplements.
nfection was carried out in the same medium for 40 h,
nd cells were harvested. The supernatants were col-
ected and frozen immediately on dry ice and subse-
uently at 270°C until further analysis. The media su-
ernatants collected from RSV A2-infected cultures were
ixed with 1/20 volume of 2 M HEPES, pH 7.4, containing
M MgSO4 as the stabilizer before freezing on dry ice.
The effects of stably expressed human MxA protein on
nfectious virus yields of RSV A2 or PIV3 were deter-
ined in either U-87-H4 (glioblastoma origin) or VA-9
(
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239RESISTANCE OF RSV A2 TO IFNs AND MxAVero or monkey kidney origin) cells in 75-cm2 flasks.
-87-CL4 and VN-5 cells that lack MxA gene expression
erved as controls. Cells were adsorbed for 2 h with RSV
2 or PIV3 at an m.o.i. of 0.1 or 1.0 PFU/cell. At 24, 48, 72,
r 96 h p.i., the media supernatants from duplicate flasks
ere collected and stored frozen until further analysis by
laque assay.
The effects of type I IFNs on RSV A2 in A549 cells that
xpress MxA or in Hep-2 cells that do not express MxA
n response to IFNs were investigated by pretreatment of
he cells for 20 h with 0–5000 U/ml IFN-a or -b, followed
y infection and harvesting of the supernatants at 40 h
.i.
etermination of infectious virus yields by plaque
ssay
Briefly, Hep-2 cell monolayers (48 h after plating) were
dsorbed for 1 h with a series of 10-fold dilutions of
ither RSV or PIV3 inoculum, and the infected monolay-
rs were left for 5–8 days under 1% methyl cellulose
verlay (in E-MEM with 1% FCS and antibiotic and anti-
ungal supplements) until plaques become visible. The
ell monolayers were stained with 0.1% crystal violet in
.5% formaldehyde and 150 mM NaCl. The stained
onolayers were washed and air-dried, and clear
laques were counted manually under light microscope.
he infectious virus yields of the IFN-treated samples
ere determined as (number of plaques/ml of culture
upernatant obtained from IFN-treated samples)/(num-
er of the plaques/ml of culture supernatant obtained
rom untreated samples) 3 100.
TT cytotoxicity assay
The effect of IFNs on the viability of the cell monolay-
rs was determined using MTT based in vitro toxicology
it (Sigma Chemical Co.). Duplicate sets of cell mono-
ayers were used for each IFN dose tested. In this sys-
em, the mitochondrial dehydrogenase enzymes of living
ells cleave the tetrazolium ring of the yellow MTT to
orm purple formazan crystals, which are insoluble in
queous solutions (Edmondson et al., 1988). The crystals
ere dissolved in acidified isopropanol, and the absor-
ance of resulting purple solution was spectrophoto-
etrically measured at 690 nm. An increase or decrease
n the viable cell number results in a concomitant change
n the amount of formazan formed, indicating the degree
f cytotoxicity caused by the indicated dose of IFNs.
estern immunoblot analysis of human MxA and RSV
iral proteins
A549 or MRC-5 cells were induced with IFN-a or -b
0–1000 U/ml) or with poly(IC) with or without DEAE-
extran for 20 h and then infected with RSV A2. About
0 h p.i., cells were harvested by separating the culture
upernatants from cell pellets. Cell pellets were lysed in che sample buffer (NOVEX) and analyzed by SDS–PAGE
or separating of intracellular MxA and viral proteins.
ypically about 20 mg of total cell protein lysate was
eparated on 4–20% gradient gels (NOVEX) under reduc-
ng conditions and transferred to an Optitran-supported
itrocellulose membrane (Schleicher and Schuell, NH)
or Western blot analysis. Duplicate membrane blots
ere blocked with a blocking buffer (5% nonfat milk in
TBS that contains 0.01 M Tris–Cl, pH 7.5, 0.15 M NaCl,
nd 0.02% Tween 20) and incubated with polyclonal
abbit antisera (1:1000 dilution) or guinea pig antisera
1:100 dilution) against human MxA or against RSV
made in rabbit, at 1:1000 dilution) prepared in the block-
ng buffer for 18 h. The membranes were washed three
imes with TTBS and incubated further for 2 h in the
locking buffer containing either goat anti-rabbit or anti-
uinea pig IgG alkaline phosphatase conjugate (1 mg/
l). After three additional washes in TBS (TTBS minus
ween 20), the blots were treated with alkaline color
evelopment solution containing nitroblue tetrazolium
nd 4-bromo-2-chloro-indoylphosphate (Promega, WI)
ccording to the supplier’s protocols.
oinfection of A549 cells with RSV and PIV3 followed
y indirect immunocytochemistry
Briefly, A549 cells (1 3 106) were either mock or pre-
reated with 1000 U/ml IFN-a for 20 h followed by infec-
ion for 2 h with (1) no virus, (2) 2500 PFU of RSV A2, (3)
00 PFU of PIV3, or (4) a combination of 2500 PFU of RSV
nd 500 PFU of PIV3. In preliminary experiments, RSV
nd PIV3 at the above-mentioned doses produced well-
eparated, distinct CPEs that may be counted manually
nder the microscope. In addition, a fivefold excess of
SV relative to PIV3 was used to enhance the chance of
oubly infected cells in coinfections. After the absorption
f virus, cell monolayers were washed, and plaque over-
ay medium (1% methyl cellulose in E-MEM with 1% FCS
nd antibiotic supplements) was added as done for
laque assays. Virus infection was allowed to take place
or 48 h by which time PIV3-specific CPEs became
learly visible. The overlay was aspirated, and cell mono-
ayers were fixed with cold acetone and methanol (1:1)
ixture for 10 min. After three washes with TTBS for 10
in each, the fixed cell monolayers were blocked with
locking buffer for 3 h and treated for 20 h with either a
ool of mouse MAbs against RSV G and F proteins (1:50
ilution) or PIV3 hemagglutinin (1:1000). Subsequently,
he cell monolayers were washed and incubated with the
econdary antibody (goat anti-mouse IgG conjugated to
orseradish peroxidase; KPL) at 1:1000 dilution for 2 h,
nd bound antibodies were stained and detected by
igmaSTAT HRP diaminobenzoate color-developing sub-
trate (Sigma Chemical Co.). Stained RSV- or PIV3-spe-
ific CPEs were counted under Zeiss Stemi SV 46 in-
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240 ATREYA AND KULKARNIerted light microscope and photographed under Olym-
us BX40 camera at 403 magnification.
Preliminary experiments demonstrated that RSV- and
IV3-specific MAbs did not react with mock-infected cell
onolayers, nor did these MAbs exhibit cross-reactivity
ith either RSV A2 or PIV3.
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